title: Necrolytic Migratory Erythema-like Skin Lesion During Gefitinib Treatment: A Rare Cutaneous Adverse Reaction.
authors.affiliation: Department of Dermatology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea.
authors.forename: Jun Young
authors.initials: JY
authors.lastname: Seong
authors.affiliation: Department of Dermatology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea.
authors.forename: Sook Hyun
authors.initials: SH
authors.lastname: Kong
authors.affiliation: Department of Dermatology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea.
authors.forename: Yu Sung
authors.initials: YS
authors.lastname: Choi
authors.affiliation: Department of Dermatology, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, Korea.
authors.forename: Ho Seok
authors.initials: HS
authors.lastname: Suh
mesh_terms: D001707:Biopsy, Needle; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000188:drug therapy; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology*; D005500:Follow-Up Studies; D000077156:Gefitinib; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D058568:Necrolytic Migratory Erythema / Q000139:chemically induced* / Q000473:pathology*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use; D035583:Rare Diseases; D018570:Risk Assessment; D028761:Withholding Treatment
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077156:Gefitinib